Autacoids and Related Drugs: Technologies and Global Markets

Report Highlights

• Global sales of autacoids and related drugs reached $94.6 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 3.2% to reach $112.6 billion by 2015.
  The autacoids market is dominated by biogenic amines, with revenues of $62.9 billion in 2009, and similar expected revenues in 2010.  This market is projected to rise at a compound annual growth rate (CAGR) of 2.5% and reach $71.1 billion by 2015.
• The second-largest category of autacoids-related drugs is polypeptide autacoids, which generated $20.1 billion in 2009 and are projected to generate $24.9 billion by 2015, for a compound annual growth rate (CAGR) of 3.3%.

INTRODUCTION 

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for autacoids and related products. The key objective is to present a comprehensive analysis of the current market for autacoids and related drugs and its future direction, and to examine the x biologic activity and usage of autacoids in the treatment of various diseases.

This report explores present and future strategies within the autacoids and related drug market, including the biogenic amines, polypeptide derivatives, lipid-derived autacoids, and endothelium-derived autacoids. Market requirements and setbacks in efforts of improvisation are discussed. An overview of autacoids and related products forms the background of this report. 

A detailed analysis of the structure of commerce in autacoids and related products has been conducted. This includes all four major categories of autacoid-related products, further divided into subcategories. Revenues are broken down by region and subcategories. Sales figures are estimated for the 5-year period from 2010 through 2015. 

Applications for autacoids and related products utilizing their theraputic benefits are also discussed separately in the report, with emphasis on results in respiratory, cardiovascular, CNS, analgesics, antiemetics, et al. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

This study was conducted to give insight into, and to categorize autacoids and related products. The industry is undergoing a transition due to generics hitting the market and other new developments. This study was conducted to provide detailed market analysis of autacoids and related products along with the factors affecting this market. As did many industries, autacoids experienced setbacks in 2009 due to the economic downturn as well as patent expirations, but some new advances may influence market growth. This study examines systemic influences in the autacoid market landscape.

Acquisition strategies and collaborations by companies are covered in this report. BCC also discusses the strengths and weaknesses of each category of the market in light of the new technologies/developments, growing competition, and changing customer needs.

INTENDED AUDIENCE

This study delves into the areas of market growth as well as decline in certain categories of autacoids and related products from the point of view of manufacturers and users. Analytical companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals, and research institutes will all find this study to be of interest. 

SCOPE OF THE STUDY

The scope of this study encompasses the autacoid-related product manufacturers and various therapeutic medical markets. BCC analyzes each market and its applications by reviewing its regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments. 

METHODOLOGY

BCC conducted a comprehensive literature search that included technical newsletters and journals, and numerous other sources. Data were collected through interviews and correspondence with various analytical/chemical/pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers as well as end users of autacoids and related products. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

ABOUT THE AUTHOR

Shalini S Dewan holds a master’s degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds from ibuprofen and 2-naphthyl acetic acid that are of potential pharmaceutical interest. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: New Developments, New Technologies; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; and The Dynamic Media, Sera and Reagent Market in Biotechnology.

BCC ONLINE SERVICES

BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:  

• Examine BCC’s complete catalog of Market Research Reports and place direct orders
• Subscribe to any of BCC’s many industry newsletters
• Read announcements of recently published reports and newly launched newsletters
• Register for BCC’s well-known conferences
• Request additional information on any BCC product
• Take advantage of special offers

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.